{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:56:51Z","timestamp":1790866611610,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Male breast cancer (MBC) is rare, accounting for approximately 1% of all breast cancers. When MBC is diagnosed simultaneously with a second primary lung cancer, treatment planning becomes particularly complex because diagnostic certainty, technical resectability, competing treatment windows, and radiotherapy safety must all be considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a 72-year-old man who was synchronously diagnosed with left invasive ductal breast carcinoma and right lower lobe poorly differentiated non-small cell lung cancer (NSCLC). The breast cancer was staged as pT\n                      <jats:sub>3<\/jats:sub>\n                      N\n                      <jats:sub>2a<\/jats:sub>\n                      M\n                      <jats:sub>0<\/jats:sub>\n                      , AJCC 8th edition stage IIIA, with strong ER\/PR expression and HER2 nonamplification. The lung lesion was pathologically diagnosed as poorly differentiated NSCLC without definitive glandular, squamous, or neuroendocrine differentiation and was staged as cT\n                      <jats:sub>3<\/jats:sub>\n                      N\n                      <jats:sub>0<\/jats:sub>\n                      M\n                      <jats:sub>0<\/jats:sub>\n                      , AJCC 8th edition stage IIB. Although stage IIB NSCLC is usually evaluated for surgery, this tumor closely involved the right lower lobe pulmonary vessels and bronchial structures, and thoracic surgeons considered upfront radical resection technically unsafe because of the risks of hemorrhage, extended resection, impaired blood supply to the remaining lobes, and loss of pulmonary function. After multidisciplinary team (MDT) discussion, the patient underwent left modified radical mastectomy, adjuvant AC-T chemotherapy, and simultaneous postmastectomy radiotherapy to the left chest wall\/regional nodes with definitive radiotherapy to the right lung lesion plus concurrent cisplatin. Imaging shortly after radiotherapy showed marked shrinkage of the right lung lesion, but subsequent CT and liver MRI suggested systemic progression with multiple hepatic lesions. The patient declined liver biopsy, received one cycle of vinorelbine plus cisplatin with Endostar, discontinued further treatment, and died of liver failure in March 2026.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates that therapeutic prioritization in synchronous double primary cancers should not be determined solely by TNM stage or chronological order of diagnosis. Instead, treatment decisions should integrate pathological distinction, tumor biology, anatomical treatability, technical resectability, curative potential, competing treatment windows, and short-term clinical threat. In selected patients, simultaneous postmastectomy radiotherapy and definitive lung radiotherapy may be feasible when supported by MDT consensus, dosimetric review, and close toxicity monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1950636","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:15:38Z","timestamp":1790864138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Synchronous double primary male breast cancer and non-small cell lung cancer: diagnostic confirmation and multidisciplinary management"],"prefix":"10.3389","volume":"13","author":[{"given":"Ye","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyou","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.2174\/1871520623666230821124008","article-title":"Male breast cancer: three case reports and a literature review","volume":"23","author":"Xin","year":"2023","journal-title":"Anticancer Agents Med Chem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40246-023-00510-7","article-title":"Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer","volume":"17","author":"Lee","year":"2023","journal-title":"Hum Genomics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: a population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/jco.19.03120","article-title":"Management of male breast cancer: aSCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG international male breast cancer program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/B:BREA.0000010701.08825.2d","article-title":"Is male breast cancer similar or different than female breast cancer?","volume":"83","author":"Anderson","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1780512","DOI":"10.3389\/fonc.2026.1780512","article-title":"Case report: long-term survival of a male patient with breast cancer complicated by lung adenocarcinoma treated with individualized therapy","volume":"16","author":"Liu","year":"2026","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.7150\/jca.25482","article-title":"Multiple primary malignant tumors\u2014a clinical analysis of 15,321 patients with malignancies at a single center in China","volume":"9","author":"Zhai","year":"2018","journal-title":"J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10484","DOI":"10.12998\/wjcc.v9.i34.10484","article-title":"Clinical features and survival of patients with multiple primary malignancies","volume":"9","author":"Wang","year":"2021","journal-title":"World J Clin Cases"},{"key":"B13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jjco\/hyag051","article-title":"Contrasting responses to neoadjuvant immunotherapy in synchronous transverse colon cancers with discordant mismatch repair status","volume":"56","author":"Omoto","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/1097-0142(197710)","article-title":"Multiple primary malignant neoplasms: historical perspectives","volume":"40","author":"Moertel","year":"1977","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1055-9965.Epi-06-0782","article-title":"Multiple cancer prevalence: a growing challenge in long-term survivorship","volume":"16","author":"Mariotto","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.21873\/anticanres.12032","article-title":"Surgical resection and outcome of synchronous and metachronous primary lung cancer in breast cancer patients","volume":"37","author":"Shoji","year":"2017","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/1759-7714.15284","article-title":"Considerations for multidisciplinary management of synchronous primary breast cancer and primary lung cancer\u2014analysis of thirty-one patients","volume":"15","author":"Chen","year":"2024","journal-title":"Thorac Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.lanepe.2024.100903","article-title":"Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study","volume":"40","author":"Allen","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"B20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00108-022-01366-0","article-title":"Treatment of early and locally advanced stages of non-small cell lung cancer","volume":"63","author":"Wiesweg","year":"2022","journal-title":"Inn Med (Heidelb)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e260017","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Riely","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/s0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1200\/jco-25-01747","article-title":"Postmastectomy radiation therapy: an ASTRO-ASCO-SSO clinical practice guideline","volume":"43","author":"Jimenez","year":"2025","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/jco.2016.69.1188","article-title":"Postmastectomy radiotherapy: an American society of clinical oncology, American society for radiation oncology, and society of surgical oncology focused guideline update","volume":"34","author":"Recht","year":"2016","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/nejm199710023371401","article-title":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial","volume":"337","author":"Overgaard","year":"1997","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/s0140-6736(98)09201-0","article-title":"Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: danish breast cancer cooperative group DBCG 82c randomised trial","volume":"353","author":"Overgaard","year":"1999","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/s1470-2045(13)70386-3","article-title":"The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. Concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/jco.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1200\/jco.2014.59.2360","article-title":"Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: american society of clinical oncology clinical practice guideline endorsement of the American society for radiation oncology evidence-based clinical practice guideline","volume":"33","author":"Bezjak","year":"2015","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1950636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:15:41Z","timestamp":1790864141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1950636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":32,"alternative-id":["10.3389\/fmed.2026.1950636"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1950636","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1950636"}}